Skip to main content
. Author manuscript; available in PMC: 2017 Feb 26.
Published in final edited form as: Neurosci Lett. 2016 Jan 22;615:83–87. doi: 10.1016/j.neulet.2016.01.033

Figure 3.

Figure 3

Involvement of protein tyrosine kinase in PAF-induced attenuation of LTP. Panel A shows the time course and average magnitude of LTP recorded from control slices (■), slices treated with PAF (○) and slices treated with PAF plus lavendustin A (LVD), a specific protein tyrosine kinase (△). As shown in the panel A, PAF decreased the magnitude of LTP and the PAF-mediated decrease of LTP was blocked by lavendustin A, a specific protein tyrosine kinase inhibitor. Panel B is a summary bar graph showing the average LTP magnitudes measured at 45 min after HFS. Note that lavendustin A blockade of PAF-mediated decrease of LTP. Application of lavendustin A along had no significant effect on LTP. ** denotes p<0.01.